Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced experimental parkinson’s-like disease

Journal of Neuroscience

Volumn 36, Issue 23, 2016, Pages 6332-6351

  Ahuja, Manuj ^a   Kaidery, Navneet Ammal ^a   Yang, Lichuan ^a,c,h   Calingasan, Noel ^c   Smirnova, Natalya ^d,e   Gaisin, Arsen ^f   Gaisina, Irina N ^g   Gazaryan, Irina ^d,i   Hushpulian, Dmitry M ^j,k   Kaddour Djebbar, Ismail ^a,b   Bollag, Wendy B ^a,b   Morgan, John C ^a,b   Ratan, Rajiv R ^d   Starkov, Anatoly A ^c   Beal, M Flint ^c   Thomas, Bobby ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e Oncology and Immunology   (Russian Federation)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h Kunming Biomed International ^*  (China)

ⁱ PACE UNIVERSITY   (United States)

^j MOSCOW STATE UNIVERSITY   (Russian Federation)

^k ValentaPharm Ltd   (Russian Federation)

more..

Author keywords

Fumarates; Inflammation; Mitochondria; MPTP; Nrf2; Oxidative stress

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; HOMOVANILLIC ACID; TRANSCRIPTION FACTOR NRF2; 3-NITROTYROSINE; CITRACONIC ACID; FUMARIC ACID DERIVATIVE; LEUKOCYTE ANTIGEN; MALEIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, MOUSE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE BRAIN LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PARKINSONIAN DISORDERS; RAT; SIGNAL TRANSDUCTION; TRANSFORMED CELL LINE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIGENS, CD; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FUMARATES; GENE EXPRESSION REGULATION; HUMANS; MALEATES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; PARKINSONIAN DISORDERS; RATS; SIGNAL TRANSDUCTION; TYROSINE;

EID: 84973345878     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0426-16.2016     Document Type: Article

References (59)

1. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, Kovacs Z, Lewerenz J, Lisak D, Maher P, Mausberg AK, Quasthoff K, Zimmermann C, Hartung HP, Methner A (2012) Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 9:163
2. Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunc-tion in the limelight of Parkinson’s disease pathogenesis. Biochim Biophys Acta 1792:651-663
3. Banerjee R, Ammal Kaidery N, Thomas B (2015) Oxidative stress in Parkin-son’s disease: role in neurodegeneration and targets for therapeutics. ACS Symposium Series
4. Blesa J, Przedborski S (2014) Parkinson’s disease: animal models and dopa-minergic cell vulnerability. Front Neuroanat 8:155
5. Brennan MS, Matos MF, Li B, Hronowski X, Gao B, Juhasz P, Rhodes KJ, Scannevin RH (2015) Dimethyl fumarate and monoethyl fumarate ex-hibit differential effects on KEAP1, NRF2 activation, and glutathione de-pletion in vitro. PLoS One 10:e0120254
6. Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP (2010) Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 13:1763-1811
7. Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, Williamson TP, Kraft AD, Lee JM, Li J, Johnson JA (2009) The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 11:497-508
8. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, Andersen JK (2007) Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degenera-tion. J Neurosci 27:13997-14006
9. Cho H, Hartsock MJ, Xu Z, He M, Duh EJ (2015) Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion. J Neuroinflammation 12:239
10. Dibbert S, Clement B, Skak-Nielsen T, Mrowietz U, Rostami-Yazdi M (2013) Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism. Arch Dermatol Res 305:447-451
11. Dinkova-Kostova AT, Baird L, Holmström KM, Meyer CJ, Abramov AY (2015) The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics. Biochem Soc Trans 43:602-610
12. Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O (2015) Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 15:339-346
13. Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingasan NY, Yang L, Tampellini D, Starkov AA, Chan RB, Di Paolo G, Pujol A, Beal MF (2012) Bezafibrate administration improves behav-ioral deficits and tau pathology in P301S mice. Hum Mol Genet 21:5091-5105
14. Eizirik DL, Sandler S, Ahnström G, Welsh M (1991) Exposure of pancreatic islets to different alkylating agents decreases mitochondrial DNA content but only streptozotocin induces long-lasting functional impairment of B-cells. Biochem Pharmacol 42:2275-2282
15. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, Gold R, Linker RA (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington’s disease. PLoS One 6:e16172
16. Ferrick DA, Neilson A, Beeson C (2008) Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 13:268-274
17. Foresti R, Bucolo C, Platania CM, Drago F, Dubois-Randé JL, Motterlini R (2015) Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacol Res 99:296-307
18. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087-1097
19. Gennari O, Montesano D, Salzano A, Albrizio S, Grumetto L (2011) Determination of dimethyl fumarate in desiccant and antimould sachets by reversed-phase liquid chromatography. Biomed Chromatogr 25: 1315-1318
20. Ghashghaeinia M, Bobbala D, Wieder T, Koka S, Bruck J, Fehrenbacher B, Röcken M, Schaller M, Lang F, Ghoreschi K (2010) Targeting glutathione by dimethylfumarate protects against experimental malaria by en-hancing erythrocyte cell membrane scrambling. Am J Physiol Cell Physiol 299:C791-C804
21. Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ, Fontenot JD (2015) DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. J Neuroimmunol 283:74-85
22. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098-1107
23. Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, Goelz S, Wiendl H, Lindå H, Ziemssen T, Baranzini SE, Käll TB, Bengel D, Olsson T, Gold R, Chan A (2011) Functional energetics of CD4-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One 6:e18506
24. Holmström KM, Baird L, Zhang Y, Hargreaves I, Chalasani A, Land JM, Stanyer L, Yamamoto M, Dinkova-Kostova AT, Abramov AY (2013) Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol Open 2:761-770
25. Huang H, Taraboletti A, Shriver LP (2015) Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes. Redox Biol 5: 169-175
26. Igarashi K, Sun J (2006) The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid Redox Sig-nal 8:107-118
27. Iniaghe LO, Krafft PR, Klebe DW, Omogbai EK, Zhang JH, Tang J (2015) Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage. Neurobiol Dis 82: 349-358
28. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322
29. Jing X, Shi H, Zhang C, Ren M, Han M, Wei X, Zhang X, Lou H (2015) Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson’s disease by enhancing Nrf2 activity. Neuroscience 286:131-140
30. Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, Williams CR, Yamamoto M, Kensler TW, Ratan RR, Sporn MB, Beal MF, Gazaryan IG, Thomas B (2013) Targeting Nrf2-mediated gene tran-scription by extremely potent synthetic triterpenoids attenuate dopami-nergic neurotoxicity in the MPTP mouse model of Parkinson’s disease. Antioxid Redox Signal 18:139-157
31. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89-116
32. Lê-Quôc K, Lê-Quôc D (1985) Crucial role of sulfhydryl groups in the mi-tochondrial inner membrane structure. J Biol Chem 260:7422-7428
33. Lin SX, Lisi L, Dello Russo C, Polak PE, Sharp A, Weinberg G, Kalinin S, Feinstein DL (2011) The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 3(2)
34. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activa-tion of the Nrf2 antioxidant pathway. Brain 134:678-692
35. Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH (2004) Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 58:429-432
36. Liu YS, Li HS, Qi DF, Zhang J, Jiang XC, Shi K, Zhang XJ, Zhang XH (2014) Zinc protoporphyrin IX enhances chemotherapeutic response of hepatoma cells to cisplatin. World J Gastroenterol 20:8572-8582
37. Liu Y, Qiu J, Wang Z, You W, Wu L, Ji C, Chen G (2015) Dimethylfumarate alleviates early brain injury and secondary cognitive deficits after experimental subarachnoid hemorrhage via activation of Keap1-Nrf2-ARE sys-tem. J Neurosurg 123:915-923
38. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408
39. Olanow CW, Kieburtz K, Schapira AH (2008) Why have we failed to achieve neuroprotection in Parkinson’s disease? Ann Neurol 64 (Suppl 2): S101-S110
40. Otterbein LE, Soares MP, Yamashita K, Bach FH (2003) Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24: 449-455
41. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U (2009) Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 129:231-234
42. Ruggieri S, Tortorella C, Gasperini C (2014) Pharmacology and clinical ef-ficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag 10:229-239
43. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116:1744-1754
44. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 341:274-284
45. Schmidt TJ, Ak M, Mrowietz U (2007) Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteinepreparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem 15:333-342
46. Sheikh SI, Nestorov I, Russell H, O’Gorman J, Huang R, Milne GL, Scannevin RH, Novas M, Dawson KT (2013) Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther 35:1582-1594.e9
47. Smirnova NA, Haskew-Layton RE, Basso M, Hushpulian DM, Payappilly JB, Speer RE, Ahn YH, Rakhman I, Cole PA, Pinto JT, Ratan RR, Gazaryan IG (2011) Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators. Chem Biol 18:752-765
48. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS (2015) Reduction of CD8() T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroin-flamm 2:e76
49. Taylor JM, Main BS, Crack PJ (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson’s disease. Neurochem Int 62:803-819
50. Thomas B, von Coelln R, Mandir AS, Trinkaus DB, Farah MH, Leong Lim K, Calingasan NY, Flint Beal M, Dawson VL, Dawson TM (2007) MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus cat-echolaminergic neurons in mice is independent of parkin activity. Neurobiol Dis 26:312-322
51. Thomas B, Banerjee R, Starkova NN, Zhang SF, Calingasan NY, Yang L, Wille E, Lorenzo BJ, Ho DJ, Beal MF, Starkov A (2012) Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopami-nergic death paradigms in the MPTP mouse model of Parkinson’s disease. Antioxid Redox Signal 16:855-868
52. Turley AE, Zagorski JW, Rockwell CE (2015) The Nrf2 activator tBHQ inhibits T cell activation of primary human CD4 T cells. Cytokine 71:289-295
53. van Kester MS, Bouwes Bavinck JN, Quint KD (2015) PML in patients treated with dimethyl fumarate. N Engl J Med 373:583-584
54. von Stedingk EM, Pavlov PF, Grinkevich VA, Glaser E (1997) Mitochon-drial protein import: modification of sulfhydryl groups of the inner mitochondrial membrane import machinery in Solanum tuberosum inhibits protein import. Plant Mol Biol 35:809-820
55. Xie X, Zhao Y, Ma CY, Xu XM, Zhang YQ, Wang CG, Jin J, Shen X, Gao JL, Li N, Sun ZJ, Dong DL (2015) Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activa-tion pathway. Br J Pharmacol 172:3929-3943
56. Yagi T, Hatefi Y (1987) Thiols in oxidative phosphorylation: thiols in the F0 of ATP synthase essential for ATPase activity. Arch Biochem Biophys 254:102-109
57. Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, Beal MF (2009) Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 4:e5757
58. Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A (2010) Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J 24:4639-4647
59. Zhang M, An C, Gao Y, Leak RK, Chen J, Zhang F (2013) Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 100:30-47